193274-82-7

Usage

Uses

Used in Pharmaceutical Synthesis:
1-BOC-3-BENZYL-PIPERIDIN-4-ONE is used as a key intermediate in the synthesis of various pharmaceuticals. Its BOC protecting group allows for mild deprotection conditions, facilitating the synthesis of complex drug molecules.
Used in Medicinal Chemistry and Drug Discovery:
In the field of medicinal chemistry and drug discovery, 1-BOC-3-BENZYL-PIPERIDIN-4-ONE is utilized as a versatile building block for the development of new therapeutic agents. Its unique structure and reactivity enable the creation of diverse chemical libraries for screening and optimization.
Used in Fine Chemicals Production:
1-BOC-3-BENZYL-PIPERIDIN-4-ONE is employed as a starting material in the production of fine chemicals, which are high-purity specialty chemicals used in various industries, including pharmaceuticals, agrochemicals, and fragrances.
Used in Advanced Materials Synthesis:
In the synthesis of advanced materials, 1-BOC-3-BENZYL-PIPERIDIN-4-ONE serves as a precursor for the development of novel materials with unique properties, such as high-performance polymers, catalysts, and sensors.
Overall, 1-BOC-3-BENZYL-PIPERIDIN-4-ONE is a crucial component in various chemical and pharmaceutical applications, owing to its stability, reactivity, and the ease of its BOC protecting group removal.

InChI:InChI=1/C17H23NO3/c1-17(2,3)21-16(20)18-10-9-15(19)14(12-18)11-13-7-5-4-6-8-13/h4-8,14H,9-12H2,1-3H3

Upstream product

• 101385-93-7 3-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 219324-21-7 1-tert-butyl 3-ethyl 3-benzyl-4-oxopiperidine-1,3-dicarboxylate 
• 188788-31-0 (3RS)-1,3-dibenzyl-piperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 864973-53-5 3-benzyl-5-(1-hydroxy-1-methyl-propyl)-3-methyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Catalytic Ring Expansions of Cyclic Alcohols Enabled by Proton-Coupled Electron Transfer

We report here a catalytic method for the modular ring expansion of cyclic aliphatic alcohols. In this work, proton-coupled electron transfer activation of an allylic alcohol substrate affords an alkoxy radical intermediate that undergoes subsequent C-C bond cleavage to furnish an enone and a tethered alkyl radical. Recombination of this alkyl radical with the revealed olefin acceptor in turn produces a ring-expanded ketone product. The regioselectivity of this C-C bond-forming event can be reliably controlled via substituents on the olefin substrate, providing a means to convert a simple N-membered ring substrate to either n+1 or n+2 ring adducts in a selective fashion.

2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists

The 2-azadecalin ring system was evaluated as a scaffold for the preparation of glucocorticoid receptor (GR) antagonists. High affinity, selective GR antagonists were discovered based on a hypothetical binding mode related to the steroidal GR antagonist R

PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE

The present invention provides a compound represented by the formula: ???wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R1 is a hydrogen atom, an optionally substituted hydroca

Treatment of insulin resistance with growth hormone secretagogues

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

Heterocyclic compounds

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula I.